Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells

BMC Clin Pharmacol. 2002 Oct 24:2:8. doi: 10.1186/1472-6904-2-8.

Abstract

Background: Desferrioxamine (DFO) is an important iron chelating agent. It has also been thought of as an agent with anti-oxidant potential as it chelates ferric iron in various parts of the body. However, there is evidence suggesting that it may paradoxically affect red blood cells (RBC) by inducing intracellular oxidant stress. To further understand the mechanism of DFO's interaction with RBC, we conducted a study to determine the effect of DFO upon RBC's redox status.

Methods: We examined NAD redox potential in intact RBC (N = 5) incubated with DFO. RBC were incubated with 6 mM DFO for 2 hours.

Results: Significant decreases in NAD redox potential were observed after incubation of RBC with 6 mM DFO. The mean decrease was 10.01 PlusMinus; 1.98% (p < 0.0004).

Conclusions: The data confirm the oxidant effect of DFO on RBC.

Publication types

  • Clinical Trial

MeSH terms

  • Deferoxamine / pharmacology*
  • Erythrocytes / drug effects*
  • Erythrocytes / metabolism
  • Humans
  • Iron Chelating Agents / pharmacology*
  • NAD / metabolism*
  • Oxidation-Reduction / drug effects
  • Oxidative Stress / drug effects*

Substances

  • Iron Chelating Agents
  • NAD
  • Deferoxamine